Tag Archives: bacterial vaginosis

The history of secnidazole

In September 2017, the FDA approved secnidazole for the treatment of bacterial vaginosis. Although new to the United States, secnidazole is a well-established anti-infective agent utilized worldwide for the treatment of various bacterial and parasitic infections. Published studies on secnidazole date back to the late 1960s, yet many U.S. healthcare providers remain unaware of the existence of this medication. This column details the history of secnidazole.

Continue reading »

Focus on sexual health | Bacterial vaginosis: Impact of sexual activity, implications for sexual health

Brooke Professional 2011
Brooke M. Faught

Bacterial vaginosis (BV) is the most prevalent vaginal infection. Although BV is not classified as a sexually transmitted infection, it is considered a sexually associated infection. As such, it may be possible to reduce the chance of developing it or at least reduce the rate of recurrences. Both acute and recurrent BV can have a direct impact on a woman’s perceptions about her body and her sexual health, which can then have an adverse effect on her sexual activities and quality of life. What can healthcare providers do to help?

Continue reading »

Considerations for partner therapy in patients with bacterial vaginosis

The author describes the relatively increased prevalence of bacterial vaginosis (BV) among women who have sex with women (WSW) and the concordance of vaginal flora between monogamous sexual partners. She suggests that these findings may represent sexual transmission of BV from one woman to another, not merely an association. She reports on the evidence for BV as a sexually transmitted infection, and suggests that more research is needed to determine whether treatment of asymptomatic but affected female partners might reduce BV recurrence in WSW.

Continue reading »

The ABCDs of bacterial vaginosis: Abnormal flora, Bothersome symptoms, Chronicity, and Differential diagnosis

Faculty:

Alisa Pascale, DNP, WHNP-BC, is a women’s health nurse practitioner at the Vulvovaginal Disorders Program & Gynecology at Massachusetts General Hospital and Clinical Instructor at MGH Institute of Health Professions, both in Boston, Massachusetts.

Intended audience: This continuing education (CE) activity has been designed to meet the educational needs of nurse practitioners who provide care for women of any age.

CE approval period: Now through December 31, 2019

Estimated time to complete this activity: 1 hour CE approval hours: 1.0 contact hours, including 0.5 contact hours of pharmacology credit (NCC code 2A)

Goal statement: To understand the abnormal vaginal ecosystem in women prone to bacterial vaginosis (BV) and to use current evidence and guidelines in treating single episodes of BV and in reducing chronic/recurrent episodes of BV. Continue reading »